Deal appetite in manufacturing is still running ahead of the market, but the tailwind is fading — and that makes knowing where to look more valuable, not less. This is a read of the manufacturing sector through Fintent’s financial-intent data: what our propensity indices mean, how we build them, which sub-sectors are pulling ahead, which are cooling, and how many companies are already showing the early signals that precede a transaction.

Key takeaways

Manufacturing sits above peer parity but is softening. M&A Propensity is 1.12 and CapRaise Propensity 1.09 (1.00 = market parity), both down over the last 30 days after a Q3 2025 peak of 1.28.

The highest deal appetite is concentrated in three sub-sectors: Biotechnology Research (M&A Propensity 2.42), Laboratory Equipment (1.52), and Aerospace & Defense (1.38).

Chemicals is the clear laggard. Chemical Manufacturing & Supply has fallen to 0.74 on M&A and 0.62 on CapRaise under PFAS-driven regulatory overhang.

We track a deep middle-market universe in the focus sub-sectors: 5,829 biotech-research, 4,226 aerospace & defense, and 1,140 laboratory-equipment companies with 25–1,000 employees.

The pipeline is already visible. In the last month, 36 middle-market companies across those three sub-sectors flashed an M&A score of 50 or higher — the early signal that typically leads an announcement by months to years.

What “propensity” actually measures

A propensity index is simply how much deal-related research activity a cohort shows versus its peers, benchmarked so that 1.00 equals market parity. A manufacturing M&A Propensity of 1.12 means the sector is generating 12% more M&A-oriented signal than the broader company universe; a reading of 0.74, as in chemicals, means 26% less. The index is unitless and comparative by design, so a sub-sector at 1.52 is not “52% likely to sell” — it is showing 52% more of the behavior that precedes deals than the average industry.

Two indices anchor the sector view. M&A Propensity blends Fintent’s Deal-Maker (M&A) and M&A scores to capture buy- and sell-side deal preparation. CapRaise Propensity is the financing analogue — the same construction applied to capital-raising intent. Read together, they separate sectors preparing to transact from sectors preparing to fund growth, and the gap between them is often the most telling part. Aerospace & Defense, for instance, runs hotter on CapRaise (1.53) than M&A (1.38), consistent with a rearmament-driven build-out rather than pure consolidation.

How the trends are built from financial-intent data

The indices are built from behavior, not headlines. Fintent continuously reads the research and disclosure footprint companies leave as they move toward a transaction — engaging investment banks, running business valuations, scoping equity and seller financing, exploring exit strategy, earn-out, and leveraged-buyout structures. Each of these is a financial-intent signal, scored and dated at the company level across the entire tracked universe.

Those company-level signals are aggregated up to the sector and benchmarked against a peer baseline. For this report the manufacturing cohort spans 54,500 companies, compared quarterly against similarly-sized firms elsewhere in the Fintent universe. The propensity index is the cohort’s signal density divided by that peer baseline. Because the inputs are early behaviors rather than announced events, the trend line moves before the deal flow does — which is the entire point of watching it.

The momentum figure is the direction of travel. Alongside each index we track the four-quarter slope. Manufacturing’s is now negative (-0.05 on M&A, -0.01 on CapRaise), meaning appetite, while still above parity, has been receding since the Q3 2025 spike. The Q2 2025 air-pocket that preceded that spike lined up with U.S. manufacturing contraction — ISM PMI fell below 50 from April through June amid tariff uncertainty (prnewswire.com) — and the rebound aligned with the Federal Reserve’s September 17, 2025 rate cut of 25 bps (ksl.com). The data reflects the macro cycle, with a lead.

The three sub-sectors to focus on

Biotechnology Research leads the sector on deal appetite by a wide margin, at an M&A Propensity of 2.42. That is more than double peer parity — the most concentrated M&A signal anywhere in manufacturing. Its low CapRaise reading (0.53) is the tell: this is a cohort being consolidated and acquired, not one raising fresh capital. For strategic and financial buyers hunting platforms and bolt-ons, this is the richest hunting ground in the sector.

Laboratory Equipment is the strongest combination of appetite and momentum, at 1.52 and quietly building (+0.10). Instrument and lab-equipment makers are attractive, recurring-revenue assets, and the rising slope says preparation activity is still accelerating rather than topping out. It is the smallest of the three cohorts, which makes early identification especially valuable — there are fewer names, and they move quickly.

Aerospace & Defense is the highest-conviction structural story, at 1.38 on M&A and 1.53 on CapRaise. It is the only focus sub-sector running hotter on financing than on M&A, reflecting an allied rearmament build-out: NATO’s March 26, 2026 annual report showed every member meeting or exceeding the 2% of GDP defense-spending target for the first time, reinforcing demand across platforms, munitions, and the supplier base (nato.int). Both consolidation and capital formation are live here at once.

Where appetite is cooling

Chemical Manufacturing & Supply is the sector’s notable decliner, at 0.74 on M&A and 0.62 on CapRaise. The drag is regulatory: the EPA’s April 10, 2024 PFAS drinking-water rule set enforceable limits with a 2029 compliance horizon, and the April 2024 designation of PFOA/PFOS as CERCLA hazardous substances raised cleanup exposure and balance-sheet risk for producers — cooling both deal appetite and new capital formation (epa.gov). Worth noting: falling appetite often precedes forced consolidation, so a cooling index is a reason to watch a sub-sector, not to ignore it.

The broadest cohort is also the softest. The catch-all “Other” grouping is outright cooling (momentum -0.08), and Electronics & Semiconductors and Agricultural & Food Processing are holding steady with slightly negative slopes. Against that backdrop, the concentration of appetite in biotech research, lab equipment, and aerospace & defense is what makes those three the sector’s focus list.

The middle-market universe we track

Behind every propensity reading is a company-level universe you can act on. In the three focus sub-sectors, Fintent tracks 5,829 Biotechnology Research companies, 4,226 Aerospace & Defense companies, and 1,140 Laboratory Equipment companies in the middle market — defined as 25 to 1,000 employees. These are the operators most likely to be in play and most likely to be missed by deal teams watching only the large caps.

What we’re tracking right now

The pipeline is not hypothetical. Over the last month, 36 of those middle-market companies crossed an M&A score of 50 or higher — 18 in Biotechnology Research, 15 in Aerospace & Defense, and 3 in Laboratory Equipment. A score at that level reflects a dense, recent cluster of the deal-preparation signals described above: bankers engaged, valuations run, financing scoped. These are the sector’s upcoming deals, visible now, before any of them are announced.